Clinical Trials/NCT04594928

NCT04594928

Completed

Phase 1

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GLPG3667 in Subjects With Moderate to Severe Plaque Psoriasis

Galapagos NV7 sites in 3 countries30 target enrollmentOctober 19, 2020

ConditionsPlaque Psoriasis

InterventionsGLPG3667 Placebo

DrugsGLPG3667 Placebo

Overview

Phase: Phase 1
Intervention: GLPG3667
Conditions: Plaque Psoriasis
Sponsor: Galapagos NV
Enrollment: 30
Locations: 7
Primary Endpoint: Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuation in subjects with moderate to severe plaque psoriasis.
Status: Completed
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this research study is to assess the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GLPG3667 in multiple daily oral doses in subjects with moderate to severe plaque psoriasis.

Registry

clinicaltrials.gov

Start Date

October 19, 2020

End Date

May 4, 2021

Last Updated

4 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Galapagos NV

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects must be male or female between 18-64 years of age (extremes included), on the date of signing the informed consent form (ICF).
•Subject must be diagnosed (for at least 6 months before screening) of moderate to severe intensity plaque psoriasis. Subject's plaque psoriasis must be stable, defined as no flare during the month before the screening visit and no change of the severity between the screening visit and baseline visit.
•At screening and at baseline (Day 1, predose), PASI \>=12 (moderate to severe) and plaque-type psoriasis covering at least 10% of total body surface area (BSA).
•At screening a Physician's Global Assessment (PGA ) score of 3 ("moderate") or 4 ("severe").
•Subject must be considered by dermatologist investigator to be a candidate for systemic therapy of plaque psoriasis (either naïve or history of previous systemic treatment).
•This list only contains the key inclusion criteria.

Exclusion Criteria

•Subject has a known hypersensitivity to investigational product (IP) ingredients or history of a significant allergic reaction to IP ingredients as determined by the investigator.
•Subjects with psoriasis other than plaque type or complicated psoriasis such as guttate, erythrodermic, exfoliative, inverse, pustular, palmo plantar, infected, or ulcerated psoriasis.
•Subject has evidence of skin conditions other than psoriasis (e.g. eczema) at the time of screening or baseline visit that would interfere with the evaluation of psoriasis.
•Subject is unable to discontinue prohibited therapies for the treatment of plaque psoriasis and/or cannot discontinue phototherapy (ultraviolet B (UVB) or psoralen and ultraviolet A (PUVA)) before the start of the study up to the end of the study.
•Subjects with current or a known or suspected history of immunosuppressive condition, history of invasive opportunistic infections (e.g. human immunodeficiency virus (HIV) infection, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis, or organ or bone marrow transplantation).
•Subjects having an active clinically significant infection or any infection requiring oral or systemic therapy within 2 weeks prior screening or subjects currently on any chronic oral or systemic antiinfective therapy for chronic infection.
•Subject testing positive for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection as detected at screening based on real time polymerase chain reaction (RT-PCR) or at baseline based on Immunoglobulin M (IgM) immunoassay, or subjects who have been in contact with SARS-CoV-2 infected individuals in the two weeks prior to first dosing of IP. Subjects presenting any signs or symptoms of SARS-Cov-2 infection as detected at screening or baseline following careful physical examination (e.g. cough, fever, headaches, fatigue, dyspnea, myalgia, anosmia, dysgeusia, anorexia, sore throat, etc.). In addition, any other locally applicable standard diagnostic criteria may also apply to diagnose SARS-CoV-2 infection.
•Subjects with evidence of active or latent infection with Mycobacterium tuberculosis (TB) as defined by:
•Positive QuantiFERON-TB Gold test result, AND/OR
•Chest radiograph (posterior anterior view) taken within 12 weeks prior to screening, read by a qualified radiologist or pulmonologist, with evidence of current active TB or old inactive TB.

Arms & Interventions

GLPG3667 Dose A

Daily doses of GLPG3667 for 4 weeks.

Intervention: GLPG3667

GLPG3667 Dose B

Daily doses of GLPG3667 for 4 weeks.

Intervention: GLPG3667

Placebo

Placebo to match will be administered as capsules for daily oral use.

Intervention: Placebo

Outcomes

Primary Outcomes

Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuation in subjects with moderate to severe plaque psoriasis.

Time Frame: From screening through study completion, an average of 3 months

To evaluate the safety and tolerability of GLPG3667 compared to placebo in subjects with moderate to severe plaque psoriasis.

Psoriasis Area and Severity Index (PASI) % change

Time Frame: At week 4

To evaluate signs of clinical efficacy of GLPG3667 compared to placebo in subjects with moderate to severe plaque psoriasis.

Secondary Outcomes

Observed GLPG3667 plasma trough concentrations (Ctrough).(Between Day 1 pre-dose and Day 30)
Change from baseline in interleukin 17 [IL-17] levels between treatment groups and time points.(Between Day 1 pre-dose and Day 60)